Biocon's Net Profits Soar In Q4FY23 By 31% YoY, Revenues Up By 58.6%

Bangalore-based pharmaceutical company Biocon on Tuesday announced its consolidated financial results for the fourth quarter that ended 31st March 2023, the company registered a 58.6 per cent rise in its consolidated revenues from operations year on year. The company's consolidated revenue for the March quarter stood at Rs 3,928 crores against Rs 2,476 crores in the same quarter last year

Biocon Reports Net Loss Of Rs 42 Cr, Sales Up By 36% YoY In Q3FY23

Biocon's revenue for the third quarter stood at Rs 3,020 crores against Rs 2,223 crores in the same quarter last year. Whereas the company posted a net loss of Rs 42 crores in quarter three of the financial year 2023(Q3FY23

Biocon Biologics Completes Acquisition Of Viatris's Biosimilar Biz

The company said that the acquisition provides it with direct commercial capabilities and supporting infrastructure in the advanced markets and several emerging markets, bringing it closer to patients, customers, and payors

Biocon Biologics partners with IDF to promote diabetes care

Biocon Biologics partners with IDF to promote diabetes care

Biocon reports 17 pc dip in Q3 net profit at Rs 169 cr

Biocon reports 17 pc dip in Q3 net profit at Rs 169 cr

Biocon Appoints Anupam Jindal As New CFO

Prior to joining Biocon, Jindal worked with the Vedanta Group of companies for 22 years where he held the position of Group Chief Financial Officer at Sterlite Technologies since 2006.

Biocon Stock Falls 2% After 28% Fall In Q1 Net Profit

The fall was due to higher research and development spend, lower profit share in biosimilars business and lower profitability in the research services segment

Biocon's Drug Itolizumab Gets DCGI Nod For Use In Moderate To Severe Covid-19 Patients

Itolizumab will be manufactured and formulated as an intravenous injection at Biocon's bio-manufacturing facility at Biocon Park in Bengaluru.

DCGI approves Itolizumab injection for restricted emergency use on COVID-19 patients

DCGI approves Itolizumab injection for restricted emergency use on COVID-19 patients

Biocon, DKSH Collaborate To Commercialise 7 Generic Formulations In SE Asia

DKSH will gain an exclusive license to register and commercialise these seven generic formulations from various therapeutic areas

Biocon Earnings : Q4FY20 Revenue Up 6% At Rs 1,644 Cr

Net Profit (before exceptional item) Up 4% at Rs 760 Cr.

Sensex Little Changed; PSU Banks Down

Among the gainers, Biocon Ltd rose as much as 6.4 percent after the company's aseptic drug product facility got Establishment Inspection Report with voluntary action by the U.S. Food and Drug Administration

Pfizer Scraps Insulin Deal With Biocon

Deutsche Cuts Biocon Target Price

Biocon Shares Fall On Lower Licensing Income